SOTYKTU
Total Payments
$23.8M
Transactions
1,112
Doctors
18
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $9.3M | 394 | 1 |
| 2023 | $14.5M | 712 | 17 |
| 2022 | $12,424 | 6 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23.8M | 1,112 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis | E.R. Squibb & Sons, L.L.C. | $2.3M | 4 |
| A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease | E.R. Squibb & Sons, L.L.C. | $1.8M | 2 |
| Phase III Study -SLE #2 - A Phase 3, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2) | E.R. Squibb & Sons, L.L.C. | $1.7M | 0 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | E.R. Squibb & Sons, L.L.C. | $1.6M | 4 |
| A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjogrens | E.R. Squibb & Sons, L.L.C. | $1.1M | 0 |
| A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With SLE | E.R. Squibb & Sons, L.L.C. | $1.1M | 0 |
| A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) | E.R. Squibb & Sons, L.L.C. | $1.1M | 2 |
| Phase III PsA #2 - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis (PsA) who are Naive to Biologic Disease Modifying Anti-rhe | E.R. Squibb & Sons, L.L.C. | $1.0M | 1 |
| A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUTING IMPACT OF DEUCRAVACITINIB ON QoL, EFFICACY AND SAFETY IN PATIENTS WITH PLAQUE PSORIASIS AND IMPAIRED HEALTH-RELATED QUALITY OF LIFE | E.R. Squibb & Sons, L.L.C. | $1.0M | 0 |
| Phase III PsA (primary WK16 driving Submission) - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Na ve to Biologic Disease-modify | E.R. Squibb & Sons, L.L.C. | $1.0M | 0 |
| Phase III PsA #2 (Wk52 driving submission) - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis (PsA) who are Naive to Biologic | E.R. Squibb & Sons, L.L.C. | $701,818 | 0 |
| COPPAR Registry with BWH | E.R. Squibb & Sons, L.L.C. | $700,000 | 0 |
| Phase II Alopecia Areata Full study through 52 wks | E.R. Squibb & Sons, L.L.C. | $688,003 | 0 |
| Phase III PsA #2 (Wk52 driving submission) - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Na ve to Biologic Disease-modifying A | E.R. Squibb & Sons, L.L.C. | $662,035 | 0 |
| Phase III SLE - A Phase 3, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) | E.R. Squibb & Sons, L.L.C. | $604,707 | 0 |
| A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) | E.R. Squibb & Sons, L.L.C. | $554,353 | 0 |
| A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus | E.R. Squibb & Sons, L.L.C. | $539,904 | 1 |
| A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) | E.R. Squibb & Sons, L.L.C. | $480,257 | 0 |
| Proof of concept study of the efficacy and safety of Deucravacitinib in the treatment of lichen planopilaris and frontal fibrosing alopecia | E.R. Squibb & Sons, L.L.C. | $470,465 | 0 |
| Phase III Long Term Roll Over Psoriasis | E.R. Squibb & Sons, L.L.C. | $420,455 | 0 |
Top Doctors Receiving Payments for SOTYKTU
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Olympia, WA | $23.6M | 1,082 |
| , MD | Dermatology | Rolling Meadows, IL | $60,939 | 1 |
| Orit Markowitz | Dermatology | New York, NY | $43,342 | 1 |
| , MD | Infectious Disease | Portland, OR | $25,775 | 3 |
| , MD | Procedural Dermatology | Rockville, MD | $15,509 | 1 |
| , MD | Dermatology | Caguas, PR | $14,000 | 1 |
| , MD | Rheumatology | Omaha, NE | $9,625 | 3 |
| , MD | Gastroenterology | Louisville, KY | $8,050 | 3 |
| , MD | Dermatology | Carolina, PR | $7,800 | 1 |
| , MD | Dermatology | San Antonio, TX | $7,628 | 1 |
| , MD | Neurological Surgery | Chicago, IL | $6,129 | 4 |
| , MD | Hypertension Specialist | Farmington, CT | $5,400 | 1 |
| , MD | Internal Medicine | Durham, NC | $4,138 | 2 |
| , MD | Gastroenterology | Chicago, IL | $4,000 | 2 |
| , MD | Clinical Cardiac Electrophysiology | Wynnewood, PA | $3,900 | 2 |
| , M.D., PH.D | Psychiatry | New Haven, CT | $1,500 | 1 |
| , MD | Dermatology | Winston Salem, NC | $1,250 | 1 |
| , MD | Student in an Organized Health Care Education/Training Program | Birmingham, AL | $1,221 | 1 |
| , MD | Pediatrics | Lubbock, TX | $492.73 | 1 |
Ad
Manufacturing Companies
- E.R. Squibb & Sons, L.L.C. $23.8M
Product Information
- Type Drug
- Total Payments $23.8M
- Total Doctors 18
- Transactions 1,112
About SOTYKTU
SOTYKTU is a drug associated with $23.8M in payments to 18 healthcare providers, recorded across 1,112 transactions in the CMS Open Payments database. The primary manufacturer is E.R. Squibb & Sons, L.L.C..
Payment data is available from 2022 to 2024. In 2024, $9.3M was paid across 394 transactions to 1 doctors.
The most common payment nature for SOTYKTU is "Unspecified" ($23.8M, 100.0% of total).
SOTYKTU is associated with 20 research studies, including "Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis" ($2.3M).